Circassia (England) a specialty company focused on controlling immune system responses closed a $21.8M Series B financing. Participants include Goldman Sachs, Invesco Perpetual, Imperial Innovations and Lansdowne Partners.

Caprotec Bioanalytics (Germany) maker of a mass-spec based compound capture platform for drug development and protein biomarker identification closed a $8.8M Series B financing. Participants include Creathor Venture, IBB Beteiligungsgesellschaft, ERP Startfonds and private investors.

Oraya (Menlo Park, CA) a ophthalmology medical device company in stealth mode has closed a $18M Series B financing. Participants include Synergy Life Science Partners and Essex Woodlands Health Ventures.

CardioVascular Systems (St. Paul, MN) is working to provide a safer more effective atherectomy device for peripheral artery disease closed a $11.22M traunche of a intended $22M Series B. Participants include Easton Hunt Capital Partners and Maverick Capital.

Primera Biosystems (Mansfield, MA) developer of novel assays and instrument systems to enable simultaneous quantitative measurement of multiples genes in a single assay closed a $21M Series B financing. Participants include Abingworth, Interwest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

Aragon Surgical (Palo Alto, CA) developer of surgical instruments for electrosurgical and laparoscopic enabling tools closed a $25M Series B financing. Participants include Bay City Capital, Integral Capital Partners, Delphi Ventures and Onset Ventures.

Pervasis Therapeutics (Cambridge, MA) is working to regulate vascular repair and restore natural blood flow to critical organs in end-stage renal disease closed a $9.75M Series B financing. Participants include Flagship Venture Partners, Polaris Venture Partners, Highland Capital Partners, and Musket Research Associates.

ProtAffin Biotechnologie (Austria) is focused on developing novel biotechnology therapeutic products for acute and chronic inflammatory diseases has closed a €4.0M Series A financing. Participants include The Entrepreneurs Fund BV, Aescap Venture Management and Z-Cube.

Aushon Biosystems (Burlington, MA) provides advanced microarray technologies to life science research, drug discovery, development and clinical diagnostics closed on a $4M traunche $7M Series B. Participant was North Bridge Venture Partners.

Nitec Pharma (Switzerland) a drug company focused on the treatment of chronic inflammatory diseases with lead indications in Rheumatoid Arthritis and Polymylagia Rheumatica, raised $26M Series B round. The deal was led by NGN Capital other participants included Atlas Venture and Global Life Science Ventures.